AU2001266696A1 - Compounds for targeting endothelial cells - Google Patents

Compounds for targeting endothelial cells

Info

Publication number
AU2001266696A1
AU2001266696A1 AU2001266696A AU6669601A AU2001266696A1 AU 2001266696 A1 AU2001266696 A1 AU 2001266696A1 AU 2001266696 A AU2001266696 A AU 2001266696A AU 6669601 A AU6669601 A AU 6669601A AU 2001266696 A1 AU2001266696 A1 AU 2001266696A1
Authority
AU
Australia
Prior art keywords
compounds
endothelial cells
targeting endothelial
targeting
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266696A
Inventor
Karen Linder
Edmund R. Marinelli
Palaniappa Nanjappan
Adrian D. Nunn
Radhakrishna Pillai
Natarajan Raju
Kondareddiar Ramalingam
Michael F. Tweedle
Mathew A. Von Wronski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Research USA Inc
Original Assignee
Bracco Research USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Research USA Inc filed Critical Bracco Research USA Inc
Publication of AU2001266696A1 publication Critical patent/AU2001266696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Composite Materials (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001266696A 2000-06-02 2001-06-04 Compounds for targeting endothelial cells Abandoned AU2001266696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58536400A 2000-06-02 2000-06-02
US09/585,364 2000-06-02
PCT/US2001/018053 WO2001091805A2 (en) 2000-06-02 2001-06-04 Compounds for targeting endothelial cells

Publications (1)

Publication Number Publication Date
AU2001266696A1 true AU2001266696A1 (en) 2001-12-11

Family

ID=24341130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266696A Abandoned AU2001266696A1 (en) 2000-06-02 2001-06-04 Compounds for targeting endothelial cells

Country Status (6)

Country Link
US (4) US7109167B2 (en)
EP (3) EP2279757A3 (en)
JP (1) JP5078212B2 (en)
AU (1) AU2001266696A1 (en)
CA (1) CA2410887C (en)
WO (1) WO2001091805A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8304395B2 (en) 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7811999B2 (en) 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US8501701B2 (en) 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7109167B2 (en) * 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8883761B2 (en) 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
JP4044740B2 (en) * 2001-05-31 2008-02-06 信越化学工業株式会社 Resist material and pattern forming method
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
ES2506142T3 (en) 2002-03-01 2014-10-13 Dyax Corp. KDR and VEGF / KDR binding peptides and their use in diagnosis
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
CA2498194A1 (en) * 2002-09-04 2004-04-29 Board Of Regents, University Of Texas System Composition, method and use of bi-functional biomaterials
US7803352B2 (en) 2003-03-07 2010-09-28 John Steele Fisher Method for continuous visualization of a blood clot or plaque in body lumen
US20040175329A1 (en) * 2003-03-07 2004-09-09 Fisher John Steele Method for continuous visualization of a body lumen
WO2004083219A1 (en) * 2003-03-20 2004-09-30 Nof Corporation Phospholipid derivative
SG173223A1 (en) * 2003-04-22 2011-08-29 Ipsen Pharma Sas Peptide vectors
WO2004105802A1 (en) * 2003-05-27 2004-12-09 Philips Intellectual Property & Standards Gmbh Tracer for medical imaging
NO20035681D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of lung cancer
NO20035683D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of prostate cancer
NO20035682D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of oesophageal cancer and Barrett's oesophagus
NO20035748D0 (en) * 2003-12-19 2003-12-19 Amersham Health As Optical imaging of vulnerable arteriosclerosis
JP2007523090A (en) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル Method for improving efficacy and safety of targeted microparticulates using decoy system
CA2560781C (en) * 2004-03-22 2011-10-11 Kode Biotech Limited Synthetic membrane anchors
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
EP2290074B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
ATE430146T1 (en) 2004-07-02 2009-05-15 Bracco Imaging Spa HIGH RELAXIVITY CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING (MRI), CONTAINING A CHELATING GROUP WITH POLYHYDROXYLATED SUBSTITUENTS
CN101389273B (en) * 2004-08-05 2012-09-05 贝勒研究院 Gene or drug delivery system
EP2287303B1 (en) 2004-11-12 2014-07-02 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
GB0522112D0 (en) * 2005-10-29 2005-12-07 Ge Healthcare Ltd Novel imaging agents for cancer
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
WO2010132402A1 (en) 2009-05-11 2010-11-18 Morria Biopharmaceuticals, Inc Lipid-polymer conjugates, their preparation and uses thereof
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
BRPI0619522B8 (en) * 2005-12-09 2021-07-27 Bracco Suisse Sa vector-phospholipid objectification conjugates, composition comprising said conjugates, ultrasound contrast agent composition and method for preparing gas-filled microvesicle comprising a phospholipid and manufacturing peptide-phospholipid conjugate having low levels of tfa
AU2011202876B2 (en) * 2006-09-06 2011-09-01 Kode Biotech Limited Fluorescent cell markers
AU2007293770B2 (en) * 2006-09-06 2011-09-29 Kode Biotech Limited Fluorescent cell markers
AU2007299828C1 (en) * 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
CA2705785A1 (en) 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
EP1935433A1 (en) * 2006-12-13 2008-06-25 Institute of Nuclear Energy Research, Atomic Energy Council A method for preparing covalent lipid-spacer-peptide conjugates
WO2008091569A2 (en) * 2007-01-23 2008-07-31 Dtherapeutics, Llc Devices, systems, and methods for promoting endothelialization
WO2008113796A1 (en) * 2007-03-21 2008-09-25 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009074569A1 (en) * 2007-12-11 2009-06-18 Bracco International Bv Targeting and therapeutic compounds with a polyproline-comprising spacer and gas-filled microvesicles comprising said compounds
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
GB0811856D0 (en) * 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
EP2470287A4 (en) 2009-08-28 2015-01-21 Univ Columbia Systems, methods, and devices for production of gas-filled microbubbles
WO2011034892A2 (en) 2009-09-15 2011-03-24 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for microbubbles
JP5355456B2 (en) * 2010-03-10 2013-11-27 日本電信電話株式会社 Quantum dot composite-containing vesicle and method for producing the same
US20140035438A1 (en) * 2011-04-12 2014-02-06 Massachusetts Institute Of Technology Passive, Self-Tuning Energy Harvester for Extracting Energy From Rotational Motion
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20140308342A1 (en) * 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
CN104774246B (en) * 2014-03-21 2018-05-04 中山大学附属肿瘤医院 NRP-1 specific tumours target polypeptide and its application
AU2017281039A1 (en) 2016-06-20 2019-01-24 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
AU2017281040A1 (en) 2016-06-20 2019-01-24 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
WO2018089556A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Coatings with tunable amine density
CN116514861A (en) * 2016-11-09 2023-08-01 库博科学公司 Preassembled, protected, chemically stable, chemically selective linker
WO2018089858A1 (en) 2016-11-11 2018-05-17 Healthtell Inc. Methods for identifying candidate biomarkers
KR102501683B1 (en) * 2022-01-18 2023-02-21 오르바이오 주식회사 Contrast agent comprising micronano bubbles and manufacturing method thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369121A (en) 1966-04-06 1968-02-13 Squibb & Sons Inc Radioactive package and container therefor
US3920995A (en) 1973-05-04 1975-11-18 Squibb & Sons Inc Radioactive material generator
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
AU2698684A (en) 1983-07-01 1985-02-07 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
ATE60340T1 (en) 1984-10-19 1991-02-15 Battelle Memorial Institute MICROORGANISM DEGRADABLE POLYPEPTIDE AND ITS USE FOR PROGRESSIVE DELIVERY OF MEDICATIONS.
CH667874A5 (en) 1985-12-19 1988-11-15 Battelle Memorial Institute BIODEGRADABLE SYNTHETIC POLYPEPTIDE AND ITS USE FOR THE PREPARATION OF MEDICAMENTS.
US4808524A (en) 1987-09-18 1989-02-28 Eastman Kodak Company Test kit and method for the determination of Streptococcus A antigen
CH672733A5 (en) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
DE4219724A1 (en) 1992-06-13 1993-12-16 Schering Ag Use of microcapsules as a contrast medium for color Doppler sonography
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
IS1685B (en) 1990-12-11 1998-02-24 Bracco International B.V. Method of making liposomes that are endowed with enhanced ability to absorb and contain foreign matter
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5558857A (en) 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
US5607661A (en) 1991-07-05 1997-03-04 Nycomed Imaging As Aggregates of x-ray microparticles for ultrasound imaging
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5261535A (en) * 1992-05-29 1993-11-16 Eastman Kodak Company Flexible photographic film package
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
DE69232539T3 (en) 1992-10-28 2007-01-04 Genentech, Inc., South San Francisco Use of anti-VEGF antibodies for the treatment of cancer
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
BR9406993A (en) 1993-07-02 1996-09-10 Molecular Biosystems Inc Microspheres of insoluble gases encapsulated with protein and their preparation and use as ultrasonic imaging agents
AU7261994A (en) 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
DE69416078T2 (en) 1993-10-22 1999-05-27 Nihon Mediphysics Co Ltd Inflammatory affinity peptides and their radiolabeled diagnostic compositions
CA2175557A1 (en) * 1993-11-16 1995-05-26 Alfred Pollak Immobilized labelling method
DE69432295T2 (en) 1993-12-15 2003-08-14 Bracco Research Sa GAS MIXTURES CAN BE USED AS ULTRASONIC CONTRAST
US5480970A (en) 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
US5569745A (en) 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
CA2187427A1 (en) 1995-02-24 1996-08-29 Herve Tournier Liposome suspensions as blood pool imaging contrast agents
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
CA2218541A1 (en) 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5833948A (en) 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
DE69628731T3 (en) 1995-11-01 2012-09-20 Bracco Suisse S.A. TARGETED MAGNETICALLY MARKED MOLECULAR MARKER SYSTEMS AS NMR IMAGING PRODUCTS
KR970048612A (en) 1995-12-29 1997-07-29 김주용 Solar Tracking System and Method Using Solar Array
SK284200B6 (en) 1996-02-19 2004-10-05 Amersham Health As Improvements in or relating to contrast agents
EP0963209A2 (en) 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
AU733477B2 (en) * 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
WO1998018501A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
AU9550498A (en) 1997-10-21 1999-05-10 Nycomed Imaging As Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug
WO1999030157A2 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Neuropilins in methods for diagnosis and prognosis of cancer
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
EP1056773A2 (en) 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
EP1068224B1 (en) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
JP2002510705A (en) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー Radiopharmaceuticals for imaging infections and inflammation, and for imaging and treating cancer
DE19820543A1 (en) 1998-05-08 1999-11-11 Dystar Textilfarben Gmbh & Co New reactive monoazo dyes useful for dyeing material containing hydroxyl or carbonamido groups
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
AU5142899A (en) * 1999-02-17 2000-09-04 Resolution Pharmaceuticals Inc. Immobilized labeling compounds and methods
US6252664B1 (en) * 1999-10-15 2001-06-26 Biocrystal Ltd. Fluorescence filter cube for fluorescence detection and imaging
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
WO2001083693A2 (en) 2000-04-28 2001-11-08 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
US7109167B2 (en) * 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2001270025B2 (en) * 2000-06-21 2005-08-18 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
DE10029565A1 (en) 2000-06-22 2002-01-10 Weims Ulrich Tool for pulling rubber valves for tubeless vehicle tires through the valve hole of the rim
MEP13708A (en) 2000-06-23 2010-06-10 Bayer Schering Pharma Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US20030133972A1 (en) 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
WO2003029275A2 (en) * 2001-10-03 2003-04-10 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1501357A4 (en) 2002-05-06 2009-10-21 Genentech Inc Use of vegf for treating bone defects
AU2003251397B2 (en) 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection
WO2009144828A1 (en) 2008-05-30 2009-12-03 株式会社アドバンテスト Wafer unit for testing and testing system

Also Published As

Publication number Publication date
CA2410887A1 (en) 2001-12-06
EP1289565A2 (en) 2003-03-12
CA2410887C (en) 2012-07-24
US20020147136A1 (en) 2002-10-10
EP1289565B1 (en) 2015-04-22
WO2001091805A3 (en) 2002-09-06
JP5078212B2 (en) 2012-11-21
US7109167B2 (en) 2006-09-19
US20060258566A1 (en) 2006-11-16
EP2279757A3 (en) 2011-08-03
WO2001091805A2 (en) 2001-12-06
EP2286843A3 (en) 2011-08-03
US20060263303A1 (en) 2006-11-23
US20110262366A1 (en) 2011-10-27
US7820621B2 (en) 2010-10-26
JP2004500854A (en) 2004-01-15
EP2279757A2 (en) 2011-02-02
EP2286843A2 (en) 2011-02-23
US7884183B2 (en) 2011-02-08

Similar Documents

Publication Publication Date Title
AU2001266696A1 (en) Compounds for targeting endothelial cells
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001228678A1 (en) Amplifier arrangement
AU2001230584A1 (en) 1h-imidazopyridine derivatives
EP1130098A3 (en) Mammalian osteoregulins
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001265089A1 (en) Rc-timer scheme
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU4430701A (en) Compounds for targeting
AU2001277697A1 (en) Accumulator
AU2000223275A1 (en) Novel triazole derivatives
AU2001270922A1 (en) Accumulator
AU2002220553A1 (en) Bioreactor
AU2001280590A1 (en) 5-substituted 2-aryl-4-pyrimidinones
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001232092A1 (en) Amplifier
AU2001258841A1 (en) Heterocyclic compounds
AU2002246543A1 (en) Energy pathway arrangement
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001220281A1 (en) Rollerboard for road-skiing